The Changing Face of Heart Transplantation

Journal of the American College of Cardiology

Volumn 52, Issue 8, 2008, Pages 587-598

  Hunt, Sharon A ^a   Haddad, François ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

cardiac surgery; coronary artery disease; heart failure; heart transplantation; immunology

Indexed keywords

ABATACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOGRAFT; CONGENITAL HEART DISEASE; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; ORGAN DONOR; ORGAN PRESERVATION; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SOUTH AFRICA; SURGICAL TECHNIQUE; SURVIVAL; VASCULAR DISEASE;

GRAFT REJECTION; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; LYMPHOCYTE ACTIVATION; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 48849100540     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.05.020     Document Type: Review

References (97)

1. Hunt S.A. Taking heart-cardiac transplantation past, present, and future. N Engl J Med 355 (2006) 231-235
2. Cooper M.A., Pommering T.L., and Koranyi K. Primary immunodeficiencies. Am Fam Physician 68 (2003) 2001-2008
3. Ventura H.O., and Muhammed K. Historical perspectives on cardiac transplantation: the past as prologue to challenges for the 21st century. Curr Opin Cardiol 16 (2001) 118-123
4. McRae D. Every Second Counts: The Race to Transplant the First Human Heart (2006), Putnam Adult, New York, NY
5. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 26 (2007) 769-781
6. Kerman R.H. Understanding the sensitized patient. Heart Fail Clin 3 (2007) 1-9
7. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 23 (2004) S187-S193
8. Hosseinpour A.R., Cullen S., and Tsang V.T. Transplantation for adults with congenital heart disease. Eur J Cardiothorac Surg 30 (2006) 508-514
9. Aliabadi A.Z., Zuckermann A.O., and Grimm M. Immunosuppressive therapy in older cardiac transplant patients. Drugs Aging 24 (2007) 913-932
10. McCarthy P.M., Quader M.A., and Hoercher K.J. Evolving strategies for surgical management of patients with severe left ventricular dysfunction. Heart Lung Circ 12 (2003) 31-38
11. Alkhaldi A., Chin C., and Bernstein D. Pediatric cardiac transplantation. Semin Pediatr Surg 15 (2006) 188-198
12. Hunt S.A. Mechanical circulatory support: new data, old problems. Circulation 116 (2007) 461-462
13. Johnson M.R., Aaronson K.D., Canter C.E., et al. Heart retransplantation. Am J Transplant 7 (2007) 2075-2081
14. Magee J.C., Barr M.L., Basadonna G.P., et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant 7 (2007) 1424-1433
15. Renlund D.G., Taylor D.O., Kfoury A.G., and Shaddy R.S. New UNOS rules: historical background and implications for transplantation management. United Network for Organ Sharing. J Heart Lung Transplant 18 (1999) 1065-1070
16. Rodeheffer R.J., Naftel D.C., Stevenson L.W., et al. Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. A multi-institutional study. Cardiac Transplant Research Database Group. Circulation 94 (1996) 2883-2889
17. West L.J., Pollock-BarZiv S.M., Dipchand A.I., et al. ABO-incompatible heart transplantation in infants. N Engl J Med 344 (2001) 793-800
18. Kuppahally S.S., Valantine H.A., Weisshaar D., et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant 7 (2007) 2388-2395
19. Gasink L.B., Blumberg E.A., Localio A.R., Desai S.S., Israni A.K., and Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 296 (2006) 1843-1850
20. Bernstein D., Naftel D., Chin C., et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation 114 (2006) 273-280
21. McCarthy P.M. Surgical management of heart failure. In: Libby P., Bonow R., Mann D., and Zipes D. (Eds). Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (2008), Saunders, Philadelphia, PA 665-685
22. Lower R.R., and Shumway N.E. Studies on orthotopic homotransplantation of the canine heart. Surg Forum 11 (1960) 18-19
23. Sievers H.H., Weyand M., Kraatz E.G., and Bernhard A. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium. Thorac Cardiovasc Surg 39 (1991) 70-72
24. Schnoor M., Schafer T., Luhmann D., and Sievers H.H. Bicaval versus standard technique in orthotopic heart transplantation: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 134 (2007) 1322-1331
25. Jeevanandam V., Russell H., Mather P., Furukawa S., Anderson A., and Raman J. Donor tricuspid annuloplasty during orthotopic heart transplantation: long-term results of a prospective controlled study. Ann Thorac Surg 82 (2006) 2089-2095
26. Jamieson R.W., and Friend P.J. Organ reperfusion and preservation. Front Biosci 13 (2008) 221-235
27. Adams A.B., Williams M.A., Jones T.R., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 111 (2003) 1887-1895
28. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351 (2004) 2715-2729
29. von Andrian U.H., and Mackay C.R. T-cell function and migration. Two sides of the same coin. N Engl J Med 343 (2000) 1020-1034
30. Biedermann B.C., and Pober J.S. Human endothelial cells induce and regulate cytolytic T cell differentiation. J Immunol 161 (1998) 4679-4687
31. Wang D., Matsumoto R., You Y., et al. CD3/CD28 costimulation-induced NF-kappaB activation is mediated by recruitment of protein kinase C-theta, Bcl10, and IkappaB kinase beta to the immunological synapse through CARMA1. Mol Cell Biol 24 (2004) 164-171
32. Hammond E.H., Yowell R.L., Nunoda S., et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 8 (1989) 430-443
33. Michaels P.J., Fishbein M.C., and Colvin R.B. Humoral rejection of human organ transplants. Springer Semin Immunopathol 25 (2003) 119-140
34. Uber W.E., Self S.E., Van Bakel A.B., and Pereira N.L. Acute antibody-mediated rejection following heart transplantation. Am J Transplant 7 (2007) 2064-2074
35. Bernstein D., Williams G.E., Eisen H., et al. Gene expression profiling distinguishes a molecular signature for grade 1B mild acute cellular rejection in cardiac allograft recipients. J Heart Lung Transplant 26 (2007) 1270-1280
36. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
37. Rodriguez E.R., Skojec D.V., Tan C.D., et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 5 (2005) 2778-2785
38. Yabu J.M., and Vincenti F. Novel immunosuppression: small molecules and biologics. Semin Nephrol 27 (2007) 479-486
39. Baran D.A. Induction therapy in cardiac transplantation: when and why?. Heart Fail Clin 3 (2007) 31-41
40. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352 (2005) 2705-2713
41. Carrier M., White M., Perrault L.P., et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 18 (1999) 1218-1223
42. Everly M.J., Bloom R.D., Tsai D.E., and Trofe J. Posttransplant lymphoproliferative disorder. Ann Pharmacother 41 (2007) 1850-1858
43. Kobashigawa J.A., Stevenson L.W., Brownfield E.D., et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant 11 (1992) 428-430
44. Miller L.W., Wolford T., McBride L.R., Peigh P., and Pennington D.G. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant 11 (1992) 431-434
45. Lubitz S.A., Baran D.A., Alwarshetty M.M., et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 699-706
46. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 (2006) 1377-1386
47. Eisen H.J. Immunosuppression on the horizon. Heart Fail Clin 3 (2007) 43-49
48. Mancini D., Pinney S., Burkhoff D., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53
49. Valantine H. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican phase III clinical trial. J Heart Lung Transplant 24 (2005) S191-S195
50. Kuppahally S., Al-Khaldi A., Weisshaar D., et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant 6 (2006) 986-992
51. Raichlin E., Khalpey Z., Kremers W., et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 84 (2007) 467-474
52. Bestetti R., Theodoropoulos T.A., Burdmann E.A., Filho M.A., Cordeiro J.A., and Villafanha D. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 81 (2006) 692-696
53. Cantarovich M. Renal protective strategies in heart transplant patients. Curr Opin Cardiol 22 (2007) 133-138
54. Vincenti F., Larsen C., Durrbach A., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353 (2005) 770-781
55. Macphee I.A., Fredericks S., Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486-1489
56. Kirklin J.K., Brown R.N., Huang S.T., et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 25 (2006) 283-288
57. Frist W.H., and Biggs V.J. Chronic myelogenous leukemia after lymphoid irradiation and heart transplantation. Ann Thorac Surg 57 (1994) 214-216
58. Marboe C.C., Billingham M., Eisen H., et al. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 24 (2005) S219-S226
59. Stehlik J., Starling R.C., Movsesian M.A., et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant 25 (2006) 1402-1409
60. Dandel M., Hummel M., Muller J., et al. Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations. Circulation 104 (2001) I184-I191
61. Valantine H.A., Fowler M.B., Hunt S.A., et al. Changes in Doppler echocardiographic indexes of left ventricular function as potential markers of acute cardiac rejection. Circulation 76 (1987) V86-V92
62. Martinez-Dolz L., Almenar L., Moro J., et al. Prognostic value of brain natriuretic peptide in heart transplant patients. J Heart Lung Transplant 26 (2007) 986-991
63. Diciolla F., Scolletta S., Berti L., et al. C2 and C0 values for monitoring cyclosporine therapy in stable heart transplant recipients. Transplant Proc 37 (2005) 1355-1359
64. Mardigyan V., Giannetti N., Cecere R., Besner J.G., and Cantarovich M. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant 24 (2005) 1614-1618
65. Aumente Rubio M.D., Arizón del Prado J.M., López Malo de Molina M.D., et al. Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. Transplant Proc 35 (2003) 1988-1991
66. Deng M.C., Eisen H.J., Mehra M.R., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 6 (2006) 150-160
67. Mehra M.R., and Uber P.A. Genomic biomarkers and heart transplantation. Heart Fail Clin 3 (2007) 83-86
68. Pham M.X., Deng M.C., Kfoury A.G., Teuteberg J.J., Starling R.C., and Valantine H. Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant 26 (2007) 808-814
69. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17 (2003) 77-88
70. Newell K.A., and Larsen C.P. Tolerance assays: measuring the unknown. Transplantation 81 (2006) 1503-1509
71. Girlanda R., Mannon R.B., and Kirk A.D. Diagnostic tools for monitoring kidney transplant recipients. Semin Nephrol 27 (2007) 462-478
72. Rose E.A., Pepino P., Barr M.L., et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 11 (1992) S120-S123
73. Zerbe T.R., Kormos R., Arena V., Griffith B., Hardesty R., and Duquesnoy R. Histocompatibility and other rejection risk factors in cardiac transplantation. Transplant Proc 23 (1991) 1155-1156
74. Kobashigawa J. Immune function in adult heart transplant patients reflects risk for organ rejection and infection. Paper presented at: International Society for Heart and Lung Transplantation Meeting; April 9-12, 2008; Boston, MA.
75. Gao S.Z., Alderman E.L., Schroeder J.S., Hunt S.A., Wiederhold V., and Stinson E.B. Progressive coronary luminal narrowing after cardiac transplantation. Circulation 82 (1990) IV269-IV275
76. Mitchell R.N., and Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 100 (2007) 967-978
77. Rahmani M., Cruz R.P., Granville D.J., and McManus B.M. Allograft vasculopathy versus atherosclerosis. Circ Res 99 (2006) 801-815
78. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 17 (1998) 744-753
79. Sipahi I., and Starling R.C. Cardiac allograft vasculopathy: an update. Heart Fail Clin 3 (2007) 87-95
80. Valantine H.A. The role of viruses in cardiac allograft vasculopathy. Am J Transplant 4 (2004) 169-177
81. Tuzcu E.M., Kapadia S.R., Sachar R., et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 45 (2005) 1538-1542
82. Raichlin E., Bae J.H., Khalpey Z., et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116 (2007) 2726-2733
83. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 (1995) 621-627
84. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 24 (2005) 1736-1740
85. Halle III A.A., DiSciascio G., Massin E.K., et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 26 (1995) 120-128
86. Montoya J.G., Giraldo L.F., Efron B., et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 33 (2001) 629-640
87. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 357 (2007) 2601-2614
88. Silveira F.P., and Husain S. Fungal infections in solid organ transplantation. Med Mycol 45 (2007) 305-320
89. Ippoliti G., Rinaldi M., Pellegrini C., and Vigano M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol 56 (2005) 101-113
90. Boyle J.M., Moualla S., Arrigain S., et al. Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation. Am J Kidney Dis 48 (2006) 787-796
91. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
92. Ojo A.O. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 27 (2007) 498-507
93. Starzl T.E., and Zinkernagel R.M. Transplantation tolerance from a historical perspective. Nat Rev Immunol 1 (2001) 233-239
94. Pierson III R.N. Tolerance in heart transplantation: the Holy Grail, or an attainable goal?. Heart Fail Clin 3 (2007) 17-29
95. Newell K.A., and Larsen C.P. Transplantation tolerance. Semin Nephrol 27 (2007) 487-497
96. Auchincloss Jr. H. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 1 (2001) 6-12
97. Millan M.T., Shizuru J.A., Hoffmann P., et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73 (2002) 1386-1391